Search

News Time is Blood! Impact of Diagnostic Delays on Prognosis of Patients with Acquired Hemophilia A

The famous slogan of neurologists in connection with strokes –⁠ 'Time is brain!' –⁠ can be modified to 'Time is blood!' for the issue of acquired hemophilia A (AHA). The factor of time plays a crucial role in the prognosis of patients with AHA –⁠ delayed diagnosis is associated with longer administration of hemostatic treatment, higher risk of relapses, and mortality.

Source: Hemophilia 16. 8. 2022

News Favorable effect of linagliptin on renal endothelial functions in patients with type 2 diabetes mellitus

Diabetic nephropathy is the cause of up to 50% of cases of end-stage chronic kidney disease. The main pathological mechanism involved in the development of the early stage of diabetic nephropathy is endothelial dysfunction. The aim of the German study was to evaluate the effects of linagliptin on endothelial function in the renal vasculature.

Source: Diabetes 1. 3. 2020

News To what extent can improvement of nutritional status through parenteral nutrition affect the results of oncological treatment?

Just like cancer patients and their caregivers, doctors often overlook the risk of malnutrition. Good nutrition can be a predictor of survival in patients with malignancies.

Source: Parenteral Nutrition 14. 11. 2022

News Prevention and Treatment of Thromboembolism in the Elderly

Despite advances in the prevention and treatment of venous thromboembolism, morbidity and mortality associated with this condition remain high in certain risk groups. An international expert group focused on the elderly in its analysis published in the Thrombosis Journal.

Source: Thromboprophylaxis 9. 6. 2022

News Safety Analysis of Baricitinib in Long-Term Treatment of Rheumatoid Arthritis

Janus kinase inhibitors are relatively new and very promising drugs, but their novelty also raises the question: Are they really safe? A brand-new analysis provides the answer by examining a cohort of patients treated for the longest duration to date.

Source: Biological Treatment 21. 8. 2020

News Chemotherapy as a Risk Factor for Severe COVID-19 Course?

During the coronavirus pandemic, patients with malignant neoplastic diseases are considered an at-risk group. Whether chemotherapy is a risk factor for a more severe course of COVID-19 was the subject of the study presented below.

Source: Antiemetic Therapy 8. 4. 2021

News Benefit of ixazomib in patients with relapsed/refractory multiple myeloma in routine clinical practice

The results of treating relapsed or refractory multiple myeloma in real-world routine clinical practice were published by a broad team of Czech experts in the journal BMC Cancer.

Source: Hematologic Malignancies 10. 3. 2021

News Contact Dermatitis in Patients with Venous Ulcers –⁠ and How to Prevent It?

The prevalence of chronic wounds increases with the rising average age, and for example, venous ulcers affect up to 2% of the global population. Materials used for wound coverage, however, present a risk for the development of contact dermatitis of allergic or irritant origin. The topic of contact dermatitis in patients with venous ulcers is covered in a review article published in the International Journal of Women’s Dermatology.

Source: Wound Healing 31. 10. 2022

News Safety of Dabigatran in Secondary Prevention of Venous Thromboembolism in Pediatric Patients

Low molecular weight heparin (LMWH) or warfarin (VKA –⁠ vitamin K antagonist) is typically used for the secondary prevention of venous thromboembolism. The DIVERSITY study extension examined the safety of dabigatran in this indication in pediatric patients.

Source: Anticoagulant Treatment 23. 2. 2022

News Prophylaxis of Thromboembolism with Low-Molecular-Weight Heparins in Oncology Patients: Efficacy and Safety of Doses Adjusted According to Anti-Xa Activity

Oncological patients undergoing surgical procedures are observed to have a high risk of thromboembolic complications. Recommended prophylactic dosing of low-molecular-weight heparins (LMWH) is often associated with subprophylactic anti-Xa activity in high-risk patients. A recently published study evaluated the efficacy and safety of administering enoxaparin in doses adjusted according to the measured anti-Xa activity.

Source: Thromboprophylaxis 28. 1. 2020

News Reduction of Mortality in Patients After Abdominal Surgery in Critical Condition Thanks to Early Supplemental Parenteral Nutrition

Ensuring adequate nutrition is an important part of therapy for critically ill patients to achieve better clinical outcomes in terms of both survival and recovery speed. The preferred option is enteral nutrition (EN), which, however, cannot be provided for many reasons to patients after acute abdominal surgery. The results of studies assessing the efficacy of parenteral nutrition (PN) in this specific group of patients are inconsistent. The purpose of the study recently published in Clinical Nutrition was therefore to evaluate the effect of early supplementary parenteral nutrition in critically ill patients after acute abdominal surgery.

Source: Parenteral Nutrition 5. 5. 2022

News Impact of Depth of Treatment Response on Outcomes of ALK+ NSCLC Treatment with Brigatinib and Crizotinib

Brigatinib inhibits anaplastic lymphoma kinase (ALK) and its notable advantage is its strong effect in patients who have developed resistance during treatment with other ALK inhibitors. It has demonstrated efficacy in patients with ALK⁺ non-small cell lung cancer (NSCLC) who are refractory to crizotinib as well as in ALK⁺ NSCLC not previously treated with an ALK inhibitor. Post hoc analysis of the ALTA-1L trial, presented as a poster at this year's American Society of Clinical Oncology (ASCO) annual meeting, addresses whether the maximum reduction in target lesions of ALK⁺ NSCLC treated with brigatinib or crizotinib correlates with overall survival (OS) and progression-free survival (PFS).

Source: Non-Small Cell Lung Cancer 12. 9. 2022

News Does empagliflozin improve the overall health of patients with heart failure with reduced LVEF?

A recently published secondary analysis of the EMPEROR-Reduced study is based mainly on the results of the KCCQ-23 questionnaire, which assesses the patient's health status from their perspective. Its goal was to verify whether the benefit of empagliflozin added to the treatment of heart failure with reduced left ventricular ejection fraction (HFrEF) depends on the initial health status and how it subsequently affects the health status of these patients over 1 year.

Source: Heart Failure 21. 6. 2022

News Cardiovascular Benefit of SGLT2 Inhibitors Confirmed

The cardiovascular (CV) benefit of SGLT2 inhibitors in type 2 diabetics, demonstrated by empagliflozin in the EMPA-REG OUTCOME study, has also been confirmed by studies with canagliflozin (CANVAS), a new analysis of the CVD REAL study involving empagliflozin, canagliflozin, and dapagliflozin, as well as individual sub-studies of the EMPA-REG OUTCOME study. These findings, presented in June 2017 at the American Diabetes Association (ADA) congress, are summarized in a recently published article in the journal Critical Pathways in Cardiology.

Source: Diabetes 31. 1. 2020

News Persistent Symptom Control with s.c. Supplementation of C1 Inhibitor in Prophylactic Treatment of HAE

The open-label extension of the COMPACT study with subcutaneous C1 inhibitor in the prophylaxis of hereditary angioedema (HAE) has brought fresh results, shedding light on the treatment's impact on the frequency of attacks and reducing the need for rescue medication.

Source: Hereditary Angioedema 14. 11. 2022